Trials / Completed
CompletedNCT05093855
Efficacy and Safety Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
A Multicenter, Open-label, Phase II Study to Explore Efficacy and Safety of BDB-001 Injection in Subjects With Moderate to Severe Hidradenitis Suppurativa
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 41 (actual)
- Sponsor
- Staidson (Beijing) Biopharmaceuticals Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to explore whether BDB-001 Injection is effective and safe in the treatment of moderate to severe hidradenitis suppurativa(HS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BDB-001 Injection | Multiple IV infusions of BDB-001 Injection diluted in sodium chloride |
Timeline
- Start date
- 2021-08-18
- Primary completion
- 2023-08-22
- Completion
- 2023-08-22
- First posted
- 2021-10-26
- Last updated
- 2023-08-29
Locations
15 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05093855. Inclusion in this directory is not an endorsement.